Working to Eradicate Gynecologic Cancers

RF6
Focused Plenary VI: Clinical Trials in Gynecologic Oncology: A Focus on Targeted Therapies

Monday, March 24, 2014: 3:35 PM-4:45 PM
Ballroom B/C (Tampa Convention Center)
Description:
Moderator:  Robert Michael Wenham, MD, MS, H. Lee Moffitt Cancer Center, Tampa, FL
3:35 PM
Moderator Introductions
R. M. Wenham
H. Lee Moffitt Cancer Center, Tampa, FL
 

 
3:41 PM
131 - Focused Plenary
A phase I study of veliparib (ABT-888) in combination with carboplatin and gemcitabine in subjects with advanced ovarian cancer
H. J. Gray1, M. Cristea2, K. M. Bell-McGuinn3, L. P. Martin4, M. W. Dudley5, W. P. Munasinghe5, V. L. Giranda5, Y. Luo5, M. D. McKee5 and G. Fleming6
1University of Washington Medical Centet, Seattle, WA, 2City of Hope, Duarte, CA, 3Memorial Sloan-Kettering Cancer Center, New York, NY, 4Fox Chase Cancer Center, Philadelphia, PA, 5AbbVie, Inc., North Chicago, IL, 6University of Chicago Medical Center, Chicago, IL
 

 
3:50 PM
132 - Focused Plenary
Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)
U. A. Matulonis1, P. Harter2, C. Gourley3, M. Friedlander4, I. B. Vergote5, G. J. S. Rustin6, A. Fielding7, S. Spencer7, T. W. Ho8 and J. A. Ledermann9
1Dana-Farber Cancer Institute, Boston, MA, 2Kliniken Essen-Mitte, Essen, Germany, 3University of Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom, 4Prince of Wales Hospital, Randwick, Australia, 5University Hospital Leuven, Leuven, Belgium, 6Mount Vernon Hospital, Middlesex, United Kingdom, 7AstraZeneca, Macclesfield, United Kingdom, 8AstraZeneca, Wilmington, DE, 9University College London, London, United Kingdom
 

 
3:59 PM
Lecturette
E. M. Swisher
University of Washington, Seattle, WA
 

 
4:05 PM
133 - Focused Plenary
Results of Gynecologic Oncology Group (GOG) 229K: a phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma
D. S. Dizon1, M. Sill2, J. M. Schilder3, K. F. McGonigle4, Z. Rahman5, D. S. Miller6, D. G. Mutch7 and K. K. Leslie8
1Massachusetts General Hospital/Harvard University, Boston, MA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3Indiana University School of Medicine, Indianapolis, IN, 4Northwest Hospital & Medical Center, Women's Cancer Care of Seattle, Seattle, WA, 5St. Francis Hospital and Medical Center, Hartford, CT, 6University of Texas Southwestern Medical Center, Dallas, TX, 7Washington University School of Medicine, St. Louis, MO, 8University of Iowa Hospitals and Clinics, Iowa City, IA
 

 
4:14 PM
134 - Focused Plenary
Outpatient treatment of malignant ascites in patients with advanced gynecologic carcinomas: a single-institution experience with intraperitoneal application of the trifunctional monoclonal antibody catumaxomab
C. M. Kurbacher, O. Horn, J. Lepique, C. Schweitzer, S. Herz and J. A. Kurbacher
Gynecological Center Bonn-Friedensplatz, Bonn, Germany
 

 
4:23 PM
135 - Focused Plenary
R-ketorolac as a GTPase inhibitor: phase 0 intraperitoneal pharmacokinetic and biologic activity in ovarian cancer patients
C. Muller1, L. G. Hudson1, S. R. Kenney1, Y. Guo1, M. Gaede1, S. F. Adams2, T. Rutledge1 and A. Wandinger-Ness1
1University of New Mexico, Albuquerque, Albuquerque, NM, 2University of New Mexico, Albuquerque, NM
 

 
4:32 PM
Lecturette
M. A. Bookman
University of Arizona Cancer Center, Tucson, AZ
 
4:37 PM
Question and Floor Discussion
 
See more of: Focused Plenary
<< Previous Course | Next Course >>